Overview
- Mangoceuticals said members of its MangoRx Direct and PeachesRx Direct programs would get “direct access” to Lilly’s Zepbound and Novo’s Wegovy via LillyDirect and NovoCare Pharmacy.
- Eli Lilly said it has no affiliation with Mangoceuticals and noted it obtained a permanent injunction after suing the company in 2024 over alleged tirzepatide copying.
- Novo Nordisk stated it was not informed of Mangoceuticals’ announcement and that it has no agreement or partnership with the company.
- Mangoceuticals’ shares jumped to $2.18 at the open on November 13 before falling to $1.19 by the close after the denials, and the company did not provide comment to reporters.
- FDA limits on routine compounding of semaglutide and tirzepatide and lower cash prices through Lilly and Novo’s direct-to-consumer channels, including recent White House-linked price moves, are reshaping the GLP-1 market.